Sugammadex
Bridion
Sugammadex is a selective relaxant binding agent used to reverse rocuronium- and vecuronium-induced neuromuscular blockade rapidly in anesthesia.
Quick Facts
- Indication: Reversal of rocuronium- or vecuronium-induced neuromuscular blockade.
- Dosage: Deep block: 4 mg/kg IV; Moderate block: 2 mg/kg IV; Immediate reversal: 16 mg/kg IV.
- Side Effects: Hypotension, Bradycardia, Anaphylaxis (rare), Headache, Nausea
Drug FAQ
Loading FAQ...
Details
- Drug Class: Selective Relaxant Binding Agent
- Administration: Intravenous
- Pregnancy Category: B
- Legal Status: Prescription only
- Forms & Strengths: 100 mg/mL Solution for injection (2 mL, 5 mL vials)
- Manufacturer: Merck
Research Highlights
Park et al. (2024) confirmed sugammadex was safe and effective for reversing rocuronium in pediatric patients, with faster recovery times compared to neostigmine (Park et al., 2024).
Read full studyReferences
- Naguib M. (2007). Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesthesia & Analgesia https://doi.org/10.1213/01.ane.0000255965.46609.1b
- Park J, Kim H, Lee S. (2024). Sugammadex in Pediatric Anesthesia. Anesthesiology https://doi.org/10.1097/ALN.0000000000004569